Trial Outcomes & Findings for LIFT Intervention in Liver Transplant Candidates (NCT NCT04836923)
NCT ID: NCT04836923
Last Updated: 2026-05-15
Results Overview
Frailty is described as a biologic syndrome of decreased physiologic reserve and increased vulnerability to health stressors. This outcome is measured by the Liver frailty index \[LFI\]. LFI is composed of 3 performance-based tests (grip strength, chair stands, and balance). Patients are classified using established cutoffs (frail: LFI ≥ 4.5, pre-frail: LFI 3.3-4.4, robust: LFI ≤ 3.2). Higher LFI scores indicate a higher degree of frailty.
COMPLETED
NA
81 participants
Baseline and final frailty assessment (mean time from baseline to final frailty assessment was 216 (± 157) days)
2026-05-15
Participant Flow
The study team proposed to employ a "Realistic Effort Action Planning" (REAP) intervention, which is a form of personality-informed motivational interviewing, in a subset of patients to determine if this enhances the LIFT intervention. Due to funding and time restrictions, the study team was unable to employ this intervention and focused solely on the LIFT intervention. The record has been revised appropriately and these details have also been provided in the Limitations section.
Participant milestones
| Measure |
LIFT Subgroup
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
"LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
|
|---|---|
|
Overall Study
STARTED
|
81
|
|
Overall Study
COMPLETED
|
54
|
|
Overall Study
NOT COMPLETED
|
27
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
LIFT Intervention in Liver Transplant Candidates
Baseline characteristics by cohort
| Measure |
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
"LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
|
|---|---|
|
Comorbidities
Hyperlipidemia
|
8 Participants
n=11 Participants
|
|
Age, Continuous
|
57.2 years
STANDARD_DEVIATION 9.9 • n=11 Participants
|
|
Sex: Female, Male
Female
|
22 Participants
n=11 Participants
|
|
Sex: Female, Male
Male
|
32 Participants
n=11 Participants
|
|
Race/Ethnicity, Customized
White
|
47 Participants
n=11 Participants
|
|
Race/Ethnicity, Customized
Black
|
4 Participants
n=11 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
1 Participants
n=11 Participants
|
|
Race/Ethnicity, Customized
Asian
|
2 Participants
n=11 Participants
|
|
BMI
|
29.2 kg/m²
STANDARD_DEVIATION 5.9 • n=11 Participants
|
|
Comorbidities
Hypertension
|
10 Participants
n=11 Participants
|
|
Comorbidities
Diabetes Mellitus II
|
11 Participants
n=11 Participants
|
|
Comorbidities
Coronary Artery Disease
|
2 Participants
n=11 Participants
|
|
Comorbidities
Chronic Kidney Disease
|
3 Participants
n=11 Participants
|
|
Beta-blocker prescribed
|
11 Participants
n=11 Participants
|
|
Etiology of Liver Disease
Hepatitis C (HCV)
|
10 Participants
n=11 Participants
|
|
Etiology of Liver Disease
Alcohol-associated liver disease (ALD)
|
15 Participants
n=11 Participants
|
|
Etiology of Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
|
10 Participants
n=11 Participants
|
|
Etiology of Liver Disease
Autoimmune Hepatitis (AIH)
|
6 Participants
n=11 Participants
|
|
Etiology of Liver Disease
Other
|
13 Participants
n=11 Participants
|
|
Decompensated
Ascites
|
31 Participants
n=11 Participants
|
|
Decompensated
Hepatic encephalopathy
|
22 Participants
n=11 Participants
|
|
Decompensated
History of Variceal Bleeding
|
27 Participants
n=11 Participants
|
|
Decompensated
History of Spontaneous Bacterial Peritonitis
|
2 Participants
n=11 Participants
|
|
Decompensated
Hepatocellular Carcinoma
|
11 Participants
n=11 Participants
|
|
Model for End-Stage Liver Disease Sodium Score (MELD-Na)
|
16.9 units on a scale
STANDARD_DEVIATION 5.8 • n=11 Participants
|
|
Baseline Liver Frailty Index
|
3.63 units on a scale
STANDARD_DEVIATION 0.60 • n=11 Participants
|
|
Baseline Frailty Status by Liver Frailty Index
Robust (LFI ≤ 3.2)
|
14 Participants
n=11 Participants
|
|
Baseline Frailty Status by Liver Frailty Index
Pre-Frail (LFI 3.3-4.4)
|
23 Participants
n=11 Participants
|
|
Baseline Frailty Status by Liver Frailty Index
Frail (LFI ≥ 4.5)
|
17 Participants
n=11 Participants
|
|
Baseline Patient-Reported Physical Function T-score
|
46.6 units on a scale
STANDARD_DEVIATION 8.3 • n=11 Participants
|
PRIMARY outcome
Timeframe: Baseline and final frailty assessment (mean time from baseline to final frailty assessment was 216 (± 157) days)Frailty is described as a biologic syndrome of decreased physiologic reserve and increased vulnerability to health stressors. This outcome is measured by the Liver frailty index \[LFI\]. LFI is composed of 3 performance-based tests (grip strength, chair stands, and balance). Patients are classified using established cutoffs (frail: LFI ≥ 4.5, pre-frail: LFI 3.3-4.4, robust: LFI ≤ 3.2). Higher LFI scores indicate a higher degree of frailty.
Outcome measures
| Measure |
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
"LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
|
|---|---|
|
Frailty
Baseline
|
3.63 score on a scale
Standard Deviation 0.60
|
|
Frailty
Post-Intervention
|
3.48 score on a scale
Standard Deviation 0.68
|
PRIMARY outcome
Timeframe: Baseline and final frailty assessment (mean time from baseline to final frailty assessment was 216 (± 157) days)Patient-reported physical quality of life was measured using a validated patient-reported outcome measure (Patient-Reported Outcomes Measurement Information System Physical Function \[PROMIS-PF\]) completed in clinic. Patient-reported physical function was measured using a validated patient-reported outcome measure: Patient-Reported Outcomes Measurement Information System Physical Function \[PROMIS-PF\] Version 2.0 - Short Form 8c. A higher PROMIS T-score represents more of the concept being measured. A score of 50 is the average for the United States general population with a standard deviation of 10. A Physical Function T-score of 60 is one SD better than average. By comparison, a Physical Function T-score of 40 is one SD worse than average. Physical Function T-Scores range from 20.3 to 60.1.
Outcome measures
| Measure |
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
"LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
|
|---|---|
|
Patient-reported Physical Function
Post-Intervention
|
46.7 score on a scale
Standard Deviation 7.9
|
|
Patient-reported Physical Function
Baseline
|
46.6 score on a scale
Standard Deviation 8.3
|
PRIMARY outcome
Timeframe: 1 month and 3 months after Enrollment, throughout the follow-up period (mean follow-up time is 259 (±190) days)Data continuously collected via TrueCoach smart phone application to document adherence to exercise regimen. If patients are unable to appropriately track adherence on the smart phone application, this data will be collected at weekly videoconference/telephone check-ins detailed below. Exercise adherence rates are defined as the number of completed or attempted exercise days/total exercise days prescribed. Overall, patients were classified as adherent to the exercise regimen if their adherence rate was ≥ 75% and partially adherent if ≥ 50%. Patients were classified as non-adherent if their adherence rate was \< 50%. The mean intervention rate was measured throughout the follow-up period (from enrollment to final assessment) - the mean follow-up time was 259 (±190) days.
Outcome measures
| Measure |
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
"LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
|
|---|---|
|
Exercise Adherence Rate
1-month adherence rate (after enrollment)
|
62 percentage of exercise adherence
Interval 0.0 to 100.0
|
|
Exercise Adherence Rate
3-month adherence rate (after enrollment)
|
60 percentage of exercise adherence
Interval 0.0 to 100.0
|
|
Exercise Adherence Rate
Mean Intervention adherence rate (throughout follow-up period, mean follow-up time was 259 days)
|
51 percentage of exercise adherence
Interval 0.0 to 100.0
|
SECONDARY outcome
Timeframe: Throughout the follow-up period (mean follow-up time is 259 (±190) days)Population: No new liver related complications (e.g., new episodes of variceal bleeding) were reported because of the LIFT intervention during the follow-up period.
Data collected from medical chart for liver related complications including but not limited to diagnosis of: ascites, hepatic encephalopathy, variceal bleeding, hepatorenal syndrome, hepatopulmonary syndrome, infection.
Outcome measures
| Measure |
LIFT Subgroup
n=54 Participants
PT evaluation, an individualized home exercise prescription (HEP), daily text message reminders to exercise and weekly telephone check-ins with team members.
"LIver FrailTy" intervention (LIFT): Novel physical therapy intervention to decrease frailty in pre-transplant patients
|
|---|---|
|
Clinical Outcomes - Liver Related Complications
No new episodes of liver related complications
|
54 Participants
|
|
Clinical Outcomes - Liver Related Complications
New episodes of liver related complications
|
0 Participants
|
Adverse Events
LIFT Subgroup
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place